<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030810</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 16/01</org_study_id>
    <secondary_id>EU-20137</secondary_id>
    <nct_id>NCT00030810</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC</brief_title>
  <official_title>Preoperative Chemoradiotherapy In Non-Small Cell Lung Cancer (NSCLC) Patients With Operable Stage IIIB Disease: A Prospective Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.&#xD;
      Combining chemotherapy with radiation therapy before surgery may shrink the tumor so that it&#xD;
      can be removed during surgery.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by&#xD;
      radiation therapy before surgery in treating patients who have stage IIIB non-small cell lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility and efficacy of sequential neoadjuvant docetaxel, cisplatin,&#xD;
           and radiotherapy followed by surgery in patients with operable stage IIIB non-small cell&#xD;
           lung cancer.&#xD;
&#xD;
        -  Determine the rate of event-free survival at 1 year in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the operability and complete resection rate in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the postoperative 30-day mortality in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the response rate, failure pattern, and overall survival in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour and cisplatin IV over 1 hour on day 1. Treatment&#xD;
      repeats every 3 weeks for 3 courses in the absence of unacceptable toxicity.&#xD;
&#xD;
      Beginning 3 weeks after the last chemotherapy dose, patients without progressive disease&#xD;
      receive radiotherapy 1-2 times daily on days 1-5, 8-12, and 15-19.&#xD;
&#xD;
      Patients undergo surgery within 3-4 weeks after completion of radiotherapy.&#xD;
&#xD;
      Patients are followed at 1 month and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-46 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of event-free survival measured 1 year after registration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operability after chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality 30 days after surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resection rate after surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperfractionated</intervention_name>
    <description>Hyperfractionated radiotherapy</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere/Cisplatin</intervention_name>
    <description>Taxotere/Cisplatin</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>conventional surgery</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed, operable stage IIIB non-small cell lung cancer&#xD;
&#xD;
               -  T4 N0-3 M0 or T1-4 N3 M0 by bronchoscopy and mediastinoscopy (required for&#xD;
                  assessment of N3 disease) or CT scan or MRI of the thorax&#xD;
&#xD;
               -  Squamous cell&#xD;
&#xD;
               -  Adenosquamous cell&#xD;
&#xD;
               -  Large cell&#xD;
&#xD;
               -  Poorly differentiated&#xD;
&#xD;
          -  No prior or concurrent metastatic disease by CT scan or MRI of the brain, bone scan,&#xD;
             and abdominal ultrasound or CT scan&#xD;
&#xD;
          -  No malignant pleural or pericardial effusion&#xD;
&#xD;
          -  No invasion of the aorta, esophagus, myocardium, or supraclavicular nodes&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and/or ALT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable cardiac disease requiring treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris (even if medically controlled)&#xD;
&#xD;
          -  No significant arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No definite contraindications for the use of corticosteroids as premedication&#xD;
&#xD;
          -  No preexisting grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No other prior or concurrent malignancy except non-melanomatous skin cancer or&#xD;
             adequately treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior significant neurologic or psychiatric disorders including psychotic&#xD;
             disorders, dementia, or seizures that would preclude informed consent&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No socioeconomic or geographical circumstances that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids except as prophylactic pretreatment medication,&#xD;
             treatment for acute hypersensitivity reactions, or chronic treatment (initiated more&#xD;
             than 6 months ago) at low-dose (no more than 20 mg methylprednisolone or equivalent)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to the chest&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior treatment in a clinical trial&#xD;
&#xD;
          -  No prior cytostatic therapy&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Stupp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009 Aug;10(8):785-93. doi: 10.1016/S1470-2045(09)70172-X. Epub 2009 Jul 13.</citation>
    <PMID>19604722</PMID>
  </results_reference>
  <results_reference>
    <citation>Pless M, Stupp R, Kann R, et al.: Preoperative chemoradiotherapy in non-small cell lung cancer (NSCLC) patients with operable stage IIIB disease: a phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). [Abstract] J Clin Oncol 25 (Suppl 18): A-18021, 685s, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26.</citation>
    <PMID>30267838</PMID>
  </results_reference>
  <results_reference>
    <citation>Früh M, Ris HB, Xyrafas A, Peters S, Mirimanoff RO, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. Ann Oncol. 2016 Oct;27(10):1971-3. doi: 10.1093/annonc/mdw251. Epub 2016 Jun 29.</citation>
    <PMID>27358380</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

